Arix Bioscience PLC: Transaction in own shares
DJ Transaction in own shares
Arix Bioscience PLC (ARIX)
Transaction in own shares
19-Apr-2021 / 17:09 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Transaction in own shares
LONDON, 19 April 2021: Arix Bioscience plc ( Arix or the Company ), a global venture capital company focused on
investing in and building breakthrough biotech companies, today announces that it purchased the following number of its
ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a
Investegate |Red Rock Resources Announcements | Red Rock Resources: Issue of Equity, Warrant Exercise and TVR
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
The Board of Maven Income and Growth VCT 3 PLC (the Company) confirms that, on 16 April 2021 and under its Dividend Investment Scheme (DIS), the Company issued and allotted 156,034 new ordinary shares of 10p each (Ordinary Shares) at a price of 57.25p per share which, under the Terms and Conditions of the DIS, is equivalent to the latest announced net asset value per share . As a result, and in accordance with the Financial Conduct Authority s Disclosure, Guidance and Transparency Rules, the Company confirms that its issued share capital as at 16 April 2021 comprises 79,259,613 Ordinary Shares, with each share carrying one voting right. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required, under the Disclosure, Guidance and Transparency Rules, to notify their interest, or a change to thei
16 April 2021 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021. Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the New Ordinary Shares ) at a conversion price of £0.0387 per Ordinary Share.
Hemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan Notes
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESSWIRE / April 16, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021.
Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the New Ordinary Shares ) at a conversion price of £0.0387 per Ordinary Share.
vimarsana © 2020. All Rights Reserved.